Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 4,713 shares at $0.66 ($3K) on 2018-12-24, disclosed to the SEC on 2018-12-26.
Open-market purchase of $3k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.65 | 3,600 | $2K | 76.1% |
| 2 | $0.66 | 1,113 | $735 | 23.9% |
| Total | $0.65 avg | 4,713 | $3K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |